MCC Releases Set of Nine Portfolio-Level Milestone and SUSAR “Timeliness” Performance Metrics
Carmel, IN, December 1, 2017-The Metrics Champion Consortium’s (MCC) Vendor Oversight Work Group has published its first set of portfolio-level metrics designed to answer high-priority vendor performance questions related to achieving timeliness goals. Specifically, the five performance metrics report whether 10 study milestones are achieved by established milestone dates. The group explored different data aggregation options and decided to define metrics that help answer the following Key Performance Questions:
Are milestones being delivered “on-time” across active studies?
Are milestones being delivered “on-time” across studies over a three-month period?
Are milestones being delivered “on-time” within each study phase (start-up, conduct,
closeout)?
“The new consensus-based portfolio-level milestone metrics represent a significant expansion of MCC’s extensive catalogue of metric definitions,” said Linda Sullivan, Co-Founder & President of MCC. “The MCC Vendor Oversight Work Group defined 10 study milestones and considered the pros and cons of different metric aggregation models when developing the metric set. We look forward to the release of additional portfolio-level vendor oversight quality, cost and relationship metrics in 2018.”
Additionally, the group defined four performance metrics measuring the timeliness of SUSAR reporting.
Each metric definition includes 15 components, including metric formula, data definitions and performance targets. MCC members are invited to visit the member portal to download the metric toolkit.
The Vendor Oversight Work Group is now exploring options for measuring sponsor/vendor relationships.
Two White Papers detailing the Vendor Oversight Work Group’s metric development process and the group’s overall approach are now available to download on the Vendor Oversight Work Group page on the MCC website.
About Metrics Champion Consortium
MCC is a trusted partner in the clinical trials industry to identify what to measure and assess the critical components of what is changing and how the industry is responding to address the changes to make improvements. We continually bring you new insights into the leading trends within the industry. For more information, please visit www.metricschampion.org.
Contact:
Jane Jones
MCC Marketing Manager
jjones@metricschampion.org
(317) 622-0266 ext. 110
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
